THU0241 Association Between Tobacco Smoking and Response to Tumor Necrosis Factor Alpha Inhibitor Treatment in Ankylosing Spondylitis: Results from the Danish Nationwide Danbio Registry

Autor: G. Kollerup, Lene Dreyer, Anne Gitte Loft, S.F. Oeftiger, Mette Holland-Fischer, P. Mosborg, F.J. Johansen, Pil Højgaard, Barbara Unger, R. Pelck, Henrik Nordin, Niels Steen Krogh, Inger Marie Jensen Hansen, Tove Lorenzen, Torben Højland Hansen, Jakob Espesen, Claus Rasmussen, Jens-Erik Beck Jensen, B. Glintborg, Stavros Chrysidis, Christine Nilsson, M.L. Hetland
Rok vydání: 2015
Předmět:
Zdroj: Annals of the Rheumatic Diseases. 74:284-285
ISSN: 1468-2060
0003-4967
DOI: 10.1136/annrheumdis-2015-eular.1531
Popis: Background Studies on the impact of smoking among patients with akylosing spondylitis (AS) treated with tumor necrosis factor alpha inhibitor therapy (TNFi) are few. Objectives To investigate the association between tobacco smoking and disease activity, treatment adherence and treatment responses among patients with AS initiating the first TNFi in routine care. Methods Observational cohort study based on the Danish nationwide DANBIO registry. Patient inclusion was from year 2000 until January 1st 2014. Kaplan-Meier plots, logistic and Cox regression analyses by smoking status (current/previous/never smoker) were calculated for treatment adherence and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50%/20mm-response. Additional stratified analyses were performed according to gender and TNFi-subtype. Results Among 1576 AS patients included in the study, 1425 (90%) had known smoking status (43% current, 40% never and 16% previous smokers). Median follow-up time was 2.02 years (IQR 0.69-5.01). At baseline, current smokers had longer disease duration (4 years (1-12)/2 years (0-10)), higher BASDAI score (61 mm (47-73)/58 mm (44-70)), Bath ankylosing spondylitis function index (BASFI) (53 mm (35-69)/46 mm (31-66)) and Bath ankylosing spondylitis metrology index (BASMI) (40 mm (20-60)/30 mm (10-50)) than never smokers (all p Conclusions In this study of AS patients treated with TNFi in clinical practise, current smokers had poorer baseline patient-reported outcomes, shorter treatment adherence and poorer treatment response compared to never smokers. Acknowledgements Thank you to all the departments of rheumatology in Denmark for reporting to the DANBIO registry Disclosure of Interest B. Glintborg: None declared, P. Hojgaard: None declared, M. Hetland: None declared, S. Chrysidis: None declared, J. Espesen: None declared, M. Holland-Fischer Consultant for: Roche, Abbvie, Speakers bureau: UCB, MSD, F. Johansen: None declared, J. Jensen: None declared, I. M. Hansen: None declared, T. Hansen: None declared, G. Kollerup Speakers bureau: MSD, N. S. Krogh: None declared, A. G. Loft Consultant for: MSD, AbbVie, Speakers bureau: MSD, Pfizer, AbbVie, T. Lorenzen: None declared, P. Mosborg: None declared, C. Nilsson: None declared, H. Nordin: None declared, S. Oeftiger: None declared, R. Pelck: None declared, C. Rasmussen: None declared, B. Unger: None declared, L. Dreyer: None declared
Databáze: OpenAIRE